| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $0.37 | - | - |
| Q1'26 | $0.31 | $0.36 | +15.7% |
| Q4'25 | $0.33 | $0.44 | +34.0% |
| Q3'25 | $0.60 | $0.69 | +15.4% |
| Q2'25 | $0.61 | $0.54 | -11.5% |
| Q1'25 | $0.48 | $0.55 | +13.8% |
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $2.8B | - | - |
| Q1'26 | $2.6B | $2.7B | +2.1% |
| Q4'25 | $2.6B | $3.0B | +14.2% |
| Q3'25 | - | $2.8B | - |
| Q2'25 | - | $2.8B | - |
| Q1'25 | - | $2.6B | - |
Market Data
BAX is currently trading at $22.73, giving Baxter International Inc. a market cap of 11.94B. Today's range spans $22.73–$23.39, with shares opening at $23.35 and moving down $0.14 (0.6%) from the prior close. DailyIQ's technical score sits at 86/100 (BUY) with a news sentiment reading of 43/100.
Over the past year BAX has traded between $15.73 and $29.35 - the current price is +44.5% off the 52-week low and -22.6% from the high. 25 analysts cover the stock with a Hold consensus and a mean 12-month target of $21.95 (range $17.00–$40.00), implying downside of -3.4%.
BAX is scoring 86/100 technically (BUY) and sits at $22.73 - in the middle of its 52-week range in its $15.73–$29.35 annual range. Sentiment at 43/100 is neutral. At 11.94B in Healthcare market cap, this is the tier where earnings revision cycles have the most impact on price: upward revisions in a large-cap company with bullish momentum tend to attract analyst upgrades, which in turn attract new institutional mandates.
What makes BAX's BUY setup (86/100) particularly actionable at 11.94B in Healthcare capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $22.73 (in the middle of its 52-week range in $15.73–$29.35), with sentiment running neutral at 43/100, the setup rewards conviction-sized positioning more than it does speculative small bets.
Sentiment gathered from recent headlines
Most recent articles, ranked by recency (click to expand).